Google AI's New Product Gemini Previewed or Set to Debut, Aiming to Surpass ChatGPT

2023-12-05

Google is set to preview Gemini, a generative AI product rivaling ChatGPT, on the web this week. Delayed, Gemini promises to be powerful, challenging Bard and ChatGPT. CEO Sundar Pichai canceled live launch events due to reliability concerns with non-English queries. Gemini's full release may not be until 2024, but it's seen as a competitive move against Microsoft's OpenAI. Gemini is a multimodal AI with image, sound, and text processing capabilities, built on a reinforcement learning system.

Read more

AI developed by DeepMind demonstrates social learning ability

2023-12-05

Google's DeepMind team created an AI system for social learning. AI agents in a virtual world imitate "experts" to learn new skills efficiently. This approach mimics human learning, allowing agents to navigate obstacles and learn from experts to reach goals faster, showcasing social learning abilities.

Read more

TSMC: The Magician Behind Artificial Intelligence

2023-12-05

TSMC unveiled AWS Graviton4 and Trainium2 chips at re:Invent. It also manufactures chips for Microsoft, Google, Apple, NVIDIA, and Intel, emphasizing its pivotal role in AI ecosystem. TSMC's advanced technology drives AI industry growth, with plans for significant expansion globally. The industry's reliance on TSMC prompts concerns over potential risks and supply chain challenges, highlighting the company's dominance in semiconductor manufacturing.

Read more

Microsoft to Invest £25 Billion in Global AI Development

2023-12-04

Microsoft to invest £2.5 billion in AI infrastructure in the UK, expanding data centers and GPUs. This aligns with a global commitment of £29.5 billion to the UK. The rise of AI is driving demand for data centers, with Microsoft also expanding in Australia and Canada. The focus is on sustainability and economic growth, creating new jobs and supporting skills training.

Read more

IBM and Bristol-Myers Squibb collaborate to advance medical GenAI.

2023-12-04

IBM and Boehringer Ingelheim partner to utilize generative AI for therapeutic antibody development, aiming to enhance patient outcomes. IBM's AI technology will improve antibody discovery speed, reducing the process time to one year. This collaboration accelerates drug development, leveraging AI to revolutionize healthcare.

Read more